Modelling the cost-effectiveness of tofacitinib for the treatment of rheumatoid arthritis in the United States.

CONCLUSIONS: Tofacitinib as a second-line therapy following methotrexate failure and as a third-line therapy following a biologic failure produces lower costs and improved quality of life compared with the current pathway of care. PMID: 29976110 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/29976110?dopt=Abstract

Source: Current Medical Research and Opinion - July 8, 2018 Category: Research Tags: Curr Med Res Opin Source Type: research